Clinical Trials Logo

Clinical Trial Summary

ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.


Clinical Trial Description

ECLIPSE is a treatment, Phase 1 multicenter, prospective, single-arm study with participants serving as their own control. This study is to enroll participants who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 cm. Participants will be followed for 5 years post their cryoablation procedure. Cryoablation is the process of destroying tissue by the application of extremely cold temperatures. Galil Medical Cryoablation Systems are used as a surgical tool in the fields of general surgery, dermatology (skin), neurology (nerves), chest surgery (including lung), Ears-Nose-Throat (ENT), gynecology, oncology (cancer), proctology (colon/rectal), and urology (kidney). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01307501
Study type Interventional
Source Boston Scientific Corporation
Contact
Status Completed
Phase N/A
Start date January 4, 2012
Completion date August 30, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Recruiting NCT05846594 - A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer Phase 4
Not yet recruiting NCT03514329 - Vapor Ablation for Localized Cancer Lesions N/A
Recruiting NCT05502913 - Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Completed NCT01543672 - Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously Phase 1/Phase 2
Completed NCT03198468 - Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) N/A
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Completed NCT04804137 - Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Recruiting NCT06343402 - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Phase 1
Recruiting NCT04940325 - Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Completed NCT05908799 - Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Active, not recruiting NCT03867175 - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Phase 3
Recruiting NCT04708483 - DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria N/A
Recruiting NCT03143322 - Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases N/A
Recruiting NCT05143970 - A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors Phase 1